68Ga-FAPI PET/CT在胃及结直肠肿瘤诊疗中的临床应用进展

Clinical application and progress of 68Ga-FAPI PET/CT in the diagnosis and treatments of gastric and colorectal tumors

  • 摘要: 成纤维细胞激活蛋白(FAP)是肿瘤相关成纤维细胞的标志性蛋白,其在多种上皮来源的恶性肿瘤中高表达,而在正常组织中几乎不表达,现已成为肿瘤诊疗的重要靶点。68Ga标记成纤维细胞激活蛋白抑制剂(FAPI)的PET/CT显像具有不受血糖水平的影响、肿瘤摄取迅速以及可获得较高的靶/本底比值图像等特点,已显示出良好的临床应用前景。胃及结直肠肿瘤具有发病隐匿、易复发转移,且腹膜转移不易检出等特点,患者预后较差。与18F-氟脱氧葡萄糖(FDG)PET/CT检查相比,68Ga-FAPI PET/CT在胃及结直肠肿瘤的诊断、分期与疗效评估中具有显著优势,目前已引起国内外学者的关注。笔者重点就68Ga-FAPI-04 PET/CT在胃及结直肠肿瘤诊疗中的临床价值和研究进展进行综述。

     

    Abstract: Fibroblast activator protein (FAP) is a marker protein of tumor-associated fibroblasts, which is highly expressed in many epithelial-derived malignant tumors but hardly expressed in normal tissues, and has become an important target for tumor diagnosis and treatment. 68Ga-labeled fibroblast activator protein inhibitor (FAPI) PET/CT imaging has the characteristics of not being affected by blood glucose level, rapid tumor uptake and it can obtain high tumor-to-background ratio images, which has shown a good prospect of clinical application. The pathogenesis of gastric and colorectal tumors is concealed, they are prone to recurrence and metastasis, peritoneal metastasis in particular are not easy to detect and the prognosis is poor. Compared with 18F-fluorodeoxyglucose (FDG) PET/CT examination, 68Ga-FAPI-04 PET/CT has significant advantages in the diagnosis, staging and efficacy evaluation of gastric and colorectal tumors, at present, it has attracted the attention of scholars at home and abroad. The author focuses on the clinical value and research progress of 68Ga-FAPI PET/CT in the diagnosis and treatments of gastric and colorectal tumors.

     

/

返回文章
返回